Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James M G Larkin

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Critical Reviews in Oncology/Hematology|July 25, 2006
Kinase inhibitors in the treatment of renal cell carcinomaJames M G Larkin, Tim Eisen
The Oncologist|November 27, 2009
Combination systemic therapy for advanced renal cell carcinomaRowan E Miller, James M G Larkin
Clinical Medicine Insights. Oncology|November 16, 2011
Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanibNaveen S Vasudev, James M G Larkin
Expert Opinion on Pharmacotherapy|August 19, 2017
Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignanciesMichael J Flynn, James M G Larkin
Expert Opinion on Investigational Drugs|May 31, 2006
Epothilones in the treatment of cancerJames M G Larkin, Stanley B Kaye
British Journal of Haematology|July 21, 2005
Mice are unsuitable for modelling ABO discordance despite strain-specific A cross-reactive natural IgMJames M G Larkin, Colin D Porter
Cancer Immunology, Immunotherapy : CII|May 23, 2006
Complement insufficiency limits efficacy in a xenograft model of hyperacute rejection for cancer therapyJames M G Larkin, Colin D Porter
European Journal of Cancer (Oxford, England : 1990)|October 3, 2008
Recent advances in the treatment of renal cell carcinoma and the role of targeted therapiesSimon Chowdhury, James M G Larkin, Martin E Gore
Nature Clinical Practice. Oncology|July 28, 2007
Drug insight: advances in renal cell carcinoma and the role of targeted therapiesJames M G Larkin, Simon Chowdhury, Martin E Gore
Nature Clinical Practice. Oncology|December 20, 2008
Sunitinib is superior to interferon alpha with respect to quality of life for patients with renal cell carcinomaLisa M Pickering, Linda Pyle, James M G Larkin
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Critical Reviews in Oncology/Hematology|July 25, 2006
Kinase inhibitors in the treatment of renal cell carcinomaJames M G Larkin, Tim Eisen
The Oncologist|November 27, 2009
Combination systemic therapy for advanced renal cell carcinomaRowan E Miller, James M G Larkin
Clinical Medicine Insights. Oncology|November 16, 2011
Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanibNaveen S Vasudev, James M G Larkin
Expert Opinion on Pharmacotherapy|August 19, 2017
Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignanciesMichael J Flynn, James M G Larkin
Expert Opinion on Investigational Drugs|May 31, 2006
Epothilones in the treatment of cancerJames M G Larkin, Stanley B Kaye
British Journal of Haematology|July 21, 2005
Mice are unsuitable for modelling ABO discordance despite strain-specific A cross-reactive natural IgMJames M G Larkin, Colin D Porter
Cancer Immunology, Immunotherapy : CII|May 23, 2006
Complement insufficiency limits efficacy in a xenograft model of hyperacute rejection for cancer therapyJames M G Larkin, Colin D Porter
European Journal of Cancer (Oxford, England : 1990)|October 3, 2008
Recent advances in the treatment of renal cell carcinoma and the role of targeted therapiesSimon Chowdhury, James M G Larkin, Martin E Gore
Nature Clinical Practice. Oncology|July 28, 2007
Drug insight: advances in renal cell carcinoma and the role of targeted therapiesJames M G Larkin, Simon Chowdhury, Martin E Gore
Nature Clinical Practice. Oncology|December 20, 2008
Sunitinib is superior to interferon alpha with respect to quality of life for patients with renal cell carcinomaLisa M Pickering, Linda Pyle, James M G Larkin
Pageof 3